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Novel aroylated phenylenediamine 
compounds enhance antimicrobial 
defense and maintain airway 
epithelial barrier integrity
Iwona t. Myszor1, Zahida parveen1, Håkan ottosson2, peter Bergman3, Birgitta Agerberth3, 
Roger strömberg2 & Gudmundur H. Gudmundsson1
Aroylated phenylenediamines (ApDs) are novel inducers of innate immunity enhancing cathelicidin 
gene expression in human bronchial epithelial cell lines. Here we present two newly developed ApDs 
and aimed at defining the response and signaling pathways for these compounds with reference to 
innate immunity and antimicrobial peptide (AMP) expression. Induction was initially defined with 
respect to dose and time and compared with the APD Entinostat (MS-275). The induction applies to 
several innate immunity effectors, indicating that APDs trigger a broad spectrum of antimicrobial 
responses. The bactericidal effect was shown in an infection model against Pseudomonas aeruginosa by 
estimating bacteria entering cells. treatment with a selected ApD counteracted Pseudomonas mediated 
disruption of epithelial integrity. this double action by inducing AMps and enhancing epithelial integrity 
for one ApD compound is unique and taken as a positive indication for host directed therapy (HDt). the 
APD effects are mediated through Signal transducer and activator of transcription 3 (STAT3) activation. 
Utilization of induced innate immunity to fight infections can reduce antibiotic usage, might be 
effective against multidrug resistant bacteria and is in line with improved stewardship in healthcare.
The airway epithelium plays a critical role in the first line of defense against respiratory pathogens. The pseu-
dostratified bronchial epithelial layer is composed of undifferentiated basal cells and mature cells tightly linked 
by adherent and tight junctions providing a stringent barrier between the host milieu and the environment1,2. 
Protection is also provided by the mucus layer at the apical surface of the airway epithelium, which is a complex 
mixture of different glycoproteins and defense components such as antimicrobial peptides (AMPs). Mucociliary 
clearance by beating cilia drives movements of the mucus layer for the removal of particles and microbes1,3–5. 
Multiple human AMPs have been identified, the major two families include the defensins (α- and β-defensins) 
and the cathelicidin-family with one dominant peptide LL-376–8. AMPs on the airway epithelial surfaces are 
expressed constitutively and can be induced by activation of pattern recognition receptors (PRRs) on the epi-
thelial cells, such as transmembrane Toll-like receptors and intracellular NOD-like receptors. Cytokines can 
also affect the AMPs expression, as confirmed for IL-17 and IL-221,9. The crucial role of AMPs in the first line 
of defense against respiratory pathogens was confirmed by using β-defensin-1 and cathelicidin deficient mice 
that were more susceptible to infections10,11. Besides broad-spectrum direct microbicidal activity, AMPs display 
immunomodulatory functions such as chemotaxis6,12. Similar to the defensins, LL-37 can also be immunomod-
ulatory, stimulating airway epithelial cell proliferation and wound healing13,14. Recently, it was shown that LL-37 
activates autophagy and promotes killing of intracellular M. tuberculosis15,16.
Human AMPs can be regarded as endogenous antibiotics because of their broad antimicrobial activity14,17. 
AMPs are important in host - pathogen interactions and could be utilized to fight infections, potentially including 
those caused by antibiotic resistant bacteria. Multidrug-resistant (MDR) pathogens are a serious threat for the 
society and healthcare as exemplified by growing number of infections with the ESKAPE pathogens (Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanni, Pseudomonas aeruginosa and 
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Enterobacter spp.), where some of these bacteria are opportunistic pathogens18,19. Specifically P. aeruginosa and 
S. aureus are pathogens causing respiratory tract infections that can be life-threatening for immunocompromised 
patients especially for those suffering from cystic fibrosis20. Therefore alternative therapies to treat infections are 
urgently needed18,19. The induction of endogenous AMPs could be an effective way of treating infections because 
many MDR strains are susceptible to different AMPs. Several different compounds inducing expression of AMPs 
to boost innate immunity have been shown effective in animal models and clinical trials for treatment of infec-
tious diseases, e.g. pulmonary tuberculosis21,22. Vitamin D3 is a direct inducer of the CAMP gene expression, the 
gene encoding the antimicrobial peptide LL-3723–25. Another potent inducer is phenylbutyrate (PBA), a short 
chain fatty acid derivative and also a histone deacetylase inhibitor (HDACi)26. Interestingly, PBA treatment of 
Shigella-infected rabbits resulted in clearance of Shigella infection and counteracted the suppression of rabbit 
cathelicidin (CAP-18) in the gut and lung epithelium27. However, PBA has a fast turnover and is converted into 
phenylacetate by β-oxidation28, therefore high doses of PBA are needed to induce AMPs expression in vitro and 
in vivo. Additional potent CAMP gene inducers described recently are Entinostat and derivatives designated 
aroylated phenylenediamines (APDs)29,30. It has been shown that Entinostat stimulates CAMP gene expression 
via activation of STAT3 and HIF-1α transcription factors in human colonic epithelial cells29. Moreover, oral 
treatment of Shigella- and Vibrio cholera- infected rabbits with Entinostat improved their survival and restored 
production of the rabbit cathelicidin CAP-18 in gut epithelial surfaces30,31. Entinostat is an HDACi undergoing 
clinical trials as adjunctive cancer therapy32. However, Entinostat has a documented cytotoxicity33,34.
In this study we tested if new APDs, designated HO53 and HO56 could stimulate innate immunity responses 
in airway epithelial cells by enhancing the expression of endogenous AMPs and if that response was effective 
against the respiratory pathogen Pseudomonas aeruginosa PAO1 strain. We used bronchial epithelial cell lines, 
exhibiting a basal-like character and with the ability to differentiate towards polarized bronchial epithelium dur-
ing air-liquid interface culture (ALI). In human bronchial epithelial cell lines, the new APDs markedly induced 
expression of the CAMP gene (encoding cathelicidin pro-LL-37/LL-37) both in monolayer and in ALI. The 
CAMP gene served as the reference, but also induction of other innate immunity genes involved in the defense 
against infections was observed. In the infection model with pretreatment of bronchial epithelial cells with the 
APDs significantly reduced the number of intracellular bacteria without exhibiting direct antibiotic properties. 
We could also demonstrate that treatment with one APD (HO53) of ALI cells counteracted the disruptive effect 
of P. aeruginosa conditioned medium by maintaining the epithelial barrier integrity. Utilizing a specific inhibitor, 
we showed that STAT3 transcription factor was involved in the HO53 mediated CAMP induction. Taken together, 
the current study might open up possibilities for using APDs as novel innate immunity modulators for host 
directed therapy (HDT) of infectious diseases.
Results
HO53 and HO56 induce CAMP gene expression in bronchial epithelial cell lines (BCi and VA10). 
Entinostat has been confirmed as a potent inducer of AMPs, with effects against bacterial infections in animal 
models30,31, but is known to possess cytotoxic properties33,34 and has limited solubility in aqueous solutions. Based 
on the structure activity relations found in the first studies on APDs30, we started to optimize the AMP-inducing 
aroylated phenylenediamines (APDs) by designing and synthesizing new alternative compounds. The criterion 
was to reduce toxicity, while retaining efficient induction of AMPs and the design was based on making more 
hydrophilic APDs. Using the previously described luciferase reporter HT29 colonic cell line for expression-anal-
ysis of the antimicrobial peptide LL-3735, we identified, among the novel APDs, HO53 and HO56 (Fig. 1a; 
Supplementary Figs S1 and S2; Supplementary Methods) as interesting AMP-inducers with high activity but 
reduced toxicity.
The present study is focused on the effect of the two new compounds HO53 and HO56 (Fig. 1a) and with 
Entinostat as comparison. HO53 and HO56 enhanced CAMP gene expression in BCi-NS1.1 cells (BCi) at 24 h 
post treatment in a dose dependent way (Fig. 1b; Supplementary Fig. S3b and S3c). Entinostat also induced 
CAMP gene expression in BCi cells at 24 h but in contrast to HO53 and HO56, the induction was not dose 
dependent (Fig. 1b; Supplementary Fig. S3a). A similar pattern of induction with HO53 and HO56 was observed 
for the bronchial epithelial cell line VA10 (Supplementary Fig. S4). A broad range of HO53 and HO56 concentra-
tions (2.5–250 µM) (Supplementary Fig. S3b and S3c) was tested and for further experiments we selected 75 µM 
for both compounds. These concentrations represented a low dose that significantly induced CAMP gene expres-
sion and had low effect on cytotoxicity and proliferation of BCi cells as compared to Entinostat, but comparable 
to PBA (Supplementary Fig. S5a and S5b). We used lower concentrations of Entinostat (2.5–50 µM) to keep the 
DMSO (solvent) concentration in the cell culture medium lower than 1% (v/v). However, there was no difference 
in the CAMP gene induction between the various concentrations of Entinostat in BCi cells and therefore we 
decided to use 10 µM in following experiments because of low cytotoxicity (Supplementary Fig. S5).
Next, we monitored CAMP gene expression over time (0–72 h) with the selected concentration of Entinostat 
(10 µM), HO53 and HO56 (both 75 µM) (Fig. 1c–e). Notably, the CAMP gene expression was increased sig-
nificantly after 12 h and 24 h of treatment with HO56 and HO53, respectively and reached maximum expres-
sion at 24 h that was maintained up to 48 h post- treatment, but declined at 72 h. A similar effect was observed 
for Entinostat, where the maximal fold induction was after 24 h and lasted until 48 h, but declined at 72 h. 
Furthermore, we tested cooperation of HO53 and HO56 with the known CAMP gene inducers PBA (2 mM) and 
vitamin D3 (1α,25-dihydroxyvitamin D3; 100 nM) (Fig. 1f). We observed a synergistic effect between vitamin D3 
and the two compounds at 24 h. However, no cooperation was observed upon treatment with PBA and HO53 or 
HO56 (Fig. 1f). Consistent with these findings, the synergistic effect after co-treatment with vitamin D3 was also 
reflected at the protein level by Western blot analyzes, where higher amount of pro-LL-37 was secreted to the cell 
culture medium (Fig. 1g). HO53 and HO56 separately and in combination with PBA did not affect the pro-LL-37 
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secretion. Taken together, our findings showed that HO53 and HO56 are novel, low toxic inducers of the CAMP 
gene expression in bronchial epithelium, working in synergy with vitamin D3.
HO53 and HO56 induce several antimicrobial effectors in a bronchial epithelial cell line (BCi). 
Further, we analyzed expression of additional antimicrobial proteins/peptides. LCN2 encoding lipocalin 2, a 
siderophore binding protein that inhibits bacterial growth in iron deficient environment36. After 48 h stimulation 
Figure 1. Enhanced induction of the CAMP gene by HO53 and HO56 in BCi cells. (a) Structure of the 
two novel aroylated phenylenediamine (APD) compounds investigated in this study, HO53 and HO56. (b) 
Induction of the CAMP gene with increasing concentration of Entinostat, HO53 and HO56 in BCi cells after 
24 h post treatment. DMSO (final concentration lower than 1%) was used as a solvent control (Solvent Ctrl). 
Each bar represents mean value of 3 independent experiments ± SEM; statistical significance was calculated 
in comparison to control cells (Ctrl) using one-way ANOVA with Dunnett’s multiple comparisons test. Time-
dependent CAMP induction by (c) Entinostat (10 μM), (d) HO53 (75 μM) and (e) HO56 (75 μM) in BCi cells, 
respectively. Bars for 2–8 h (for HO53 and HO56) and bars for 2–12 h (for Entinostat) represent values from 
two technical repeats. Bars for 12–72 h (for HO53 and HO56) and bars for 24–72 h (for Entinostat) are mean 
values of 3 independent experiments ± SEM; statistical significance was calculated in comparison to control 
cells (Ctrl) using one-way ANOVA with Sidak’s multiple comparisons test. (f) Cooperation of HO53 and 
HO56 (both at 75 μM) with sodium 4-phenylbutyrate (PBA; 2 mM) or 1α,25-dihyroxyvitamin D3 (VitD3; 
100 nM) for the induction of the CAMP gene at 24 h and 48 h. Each bar represents mean value of 3 independent 
experiments ± SEM; statistical significance was calculated in comparison to HO53 (red) and HO56 (black) 
using two-way ANOVA with Dunnett’s multiple comparisons test. (g) Concentrated culture medium after 
24 h stimulation was used for Western blot analyses using monoclonal antibody against LL-37. Positive control 
included 2 ng of synthetic LL-37 peptide. GAPDH analyzed in cell lysates was used as a loading control. 
The representative Western blot is one of 3 independent experiments. The full-length blots are presented in 
Supplementary Figure S10a. For all qRT-PCR experiments the CAMP gene expression was normalized to TUBB 
(tubulin-β) reference gene and presented as fold change of the expression compared to control cells (Ctrl) set as 
1. Symbols for statistical analysis indicate p-values *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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with Entinostat, HO53 and HO56, the expression of LCN2 at mRNA level was significantly increased (approx-
imately 20–30 times) (Fig. 2a). The analyses at protein level revealed low induction of lipocalin 2 (also called 
Neutrophil gelatinase-associated lipocalin, NGAL) by Entinostat at 24 and 48 h and the representative relative 
NGAL/GAPDH ratio normalized to control was 1.85 and 1.45, respectively (Fig. 2b and Supplementary Table S2). 
In contrast to Entinostat, the induction of lipocalin 2 with HO53 and HO56 was prominent at 24 h (the repre-
sentative relative NGAL/GAPDH ratio normalized to control was 6.56 and 6.98 respectively) and decreased at 
48 h (2.24 and 2.23 for HO53 and HO56, respectively) (Fig. 2b and Supplementary Table S2). HBD1 encoding the 
human β-defensin-1 antimicrobial peptide37 was significantly induced by Entinostat, HO53 and HO56 at mRNA 
level (Fig. 2c). Significant induction of human β-defensin-1 antimicrobial peptide at the protein level analyzed by 
ELISA was observed at 48 h (Fig. 2d). In addition, the S100A8 gene encoding a unit of calprotectin antimicrobial 
protein38 was significantly induced by Entinostat (approximately 10 times) after 24 h stimulation, whereas induc-
tion with HO53 and HO56 was not significant (Fig. 2e). In contrast, the expression of lysozyme (LYZ), lactoferrin 
(LTF) and β-defensin 2 (HBD2) at mRNA levels was not detected in monolayer BCi cells. In summary the APD 
compounds affected multiple innate antimicrobial effectors in bronchial undifferentiated epithelial cells.
Figure 2. Enhanced expression of antimicrobial effectors by HO53 and HO56 stimulation in BCi cells. Samples 
were collected after 24 h (black bars) and 48 h (grey bars) post stimulation with Entinostat (10 μM), HO53 
(75 μM) and HO56 (75 μM). Followed by expression analysis at mRNA and protein level by qRT-PCR and 
ELISA/Western blot, respectively. (a) Expression of LCN2 (lipocalin 2) at mRNA and (b) protein (lipocalin 
2, NGAL) level in cell lysates. The representative Western blot is selected from one of the 3 independent 
experiments. GAPDH was used as a loading control. Full-length blots are presented in Supplementary 
Figure S10b. (c) Fold change of HBD1 (human β-defensin 1) mRNA in comparison to control (Ctrl) and 
(d) secretion of hBD-1 peptide measured by ELISA in cell culture supernatants. (e) S100A8 expression was 
analyzed by qRT-PCR. TUBB (tubulin-β) was the reference gene in qRT-PCR. Each bar represents mean value 
of 3 independent experiments ± SEM; statistical significance was calculated in comparison to the control 
group using two-way ANOVA with Dunnett’s multiple comparisons test; *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001. Significant changes are highlighted.
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HO53 and HO56 affect cytokine profiles in bronchial epithelial cell line (BCi). We also evaluated 
the effect of Entinostat, HO53 and HO56 on the induction of the pro-inflammatory mediators IL-8 (CXCL8) 
and TNFα. Upon induction with Entinostat and HO56 a significant induction of mRNA for IL-8 was observed 
(Fig. 3a). However, at the protein level significantly increased secretion of IL-8 in cell supernatants was observed 
for the three inducing compounds (Fig. 3b). Induction of TNFα mRNA expression for three inducing com-
pounds was observed only at 24 h (Fig. 3c) but at the protein level significant increased secretion was detected 
only in cell supernatants from Entinostat and HO53 stimulated culture at 48 h (Fig. 3d). In summary the APD 
compounds Entinostat, HO53 and HO56 affected the expression and release of specific cytokines and chemok-
ines, indicating potent enhancement of innate immunity defenses in bronchial epithelial cells.
HO53 and HO56 enhance antibacterial activity of the human bronchial epithelial cells (BCi). 
We observed that HO53 and HO56 treatment enhanced production of AMPs and other innate immunity factors 
in human bronchial epithelial cells. Therefore, we tested if HO53 and HO56 treatment was effective in inducing 
a functional antimicrobial response in BCi cells against the respiratory pathogen Pseudomonas aeruginosa strain 
PAO1 (Fig. 4). BCi cells were treated for 24 h with HO53 and HO56, then infected for 1 h with multiplicity of 
infection (MOI) ~40, remaining extracellular bacteria were eliminated by treatment with gentamicin and the 
number of intracellular bacteria were enumerated as colony forming units (CFU). The number of intracellular 
PAO1 was significantly lower after HO53 (~75%) and HO56 (~60%) treatment in comparison to the PAO1 num-
ber in untreated control cells (100%; equal to ~1.0 × 104 intracellular PAO1) (Fig. 4a). The treatment with low 
doses of gentamicin (0.5 µg/ml), a cell impermeable antibiotic, served as a positive control and reduced PAO1 
entry to the cells about 50%. We performed an analogous experiment to the infection assay but in the absence of 
the BCi cells (Fig. 4b). After 1 h direct exposure of PAO1 to HO53 and HO56 in the cell culture medium, there 
was no significant differences in CFU counts (Fig. 4b). Furthermore, HO53 and HO56 did not inhibit PAO1 
growth in Luria Bertani (LB) medium over time and did not kill bacteria after 2 h of direct exposure (Fig. 4c,d). 
To verify if the reduction of the intracellular PAO1 number was caused by induced antimicrobial polypeptides, 
we excluded additional antimicrobial effector systems that are involved in the defense of the epithelial surfaces, 
by analyzing the production of reactive oxygen species (ROS) (Supplementary Fig. S6a) and nitric oxide (NO) 
(Supplementary Fig. S6b, S6c)39,40. These findings indicated that the reduction of intracellular bacterial number 
Figure 3. HO53 and HO56 alter expression of cytokines in BCi cells. Expression of (a) CXCL8 and (c) TNF at 
mRNA level was analyzed by qRT-PCR and normalized to TUBB (tubulin-β) reference gene. The secretion of 
the proteins (b) IL8 (CXCL8) and (d) TNFα was evaluated by ELISA in corresponding cell culture medium. 
Analysis was performed at 24 h (black bars) and 48 h (grey bars) after stimulation with Entinostat (10 μM), 
HO53 (75 μM) and HO56 (75 μM). For all experiment each bar represents mean value of 3 independent 
experiments ± SEM; statistical significance was calculated in comparison to the untreated control cells (Ctrl) 
using two-way ANOVA with Dunnett’s multiple comparisons test; *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001. Significant changes are highlighted.
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was due to induced antimicrobial responses in human bronchial epithelial cells, but not any direct activity of the 
two APD compounds.
HO53 and HO56 induce several innate immunity genes in polarized bronchial epithelial cells. 
In order to transfer our findings into a more clinically relevant context, we tested if HO53 and HO56 treat-
ment was effective in stimulating antimicrobial responses in polarized mature epithelium, mimicking the human 
bronchi41, we analyzed expression of AMPs in differentiated BCi cells. The mRNA levels of LCN2 and S100A8 
were significantly higher compared to untreated cells, especially after 24 h post-treatment with HO56 (~4 and 
~40 fold, respectively) (Fig. 5a,b). We also observed increased protein levels of lipocalin 2 (NGAL) and S100A8 
after 24 and 48 h of treatment with HO53 and HO56. However, induction of lipocalin 2 was more pronounced 
after 48 h (Fig. 5c). Further, we analyzed the effects of HO53 and HO56 treatment on the expression of the genes 
CAMP, HBD1 and LYZ in differentiated BCi cells (ALI). The CAMP gene expression was on a similar level as 
the cells in monolayer (upregulated about 15-times) but that effect was not observed after 48 h of treatment with 
HO53 and HO56 (Fig. 5d). The enhanced expression of HBD1 (Fig. 5e) and LYZ (Fig. 5f) upon treatment with 
HO53 and HO56 was significantly higher (~10 times and 3 times, respectively). Furthermore, the expression of 
pro-inflammatory cytokines/chemokines was not significantly upregulated, except the expression of IL1B after 
Figure 4. HO53 and HO56 enhance antimicrobial response in BCi cells but are not directly bactericidal.  
(a) Effect of APDs treatment on Pseudomonas aeruginosa PAO1 invasion of BCi cells. Cells were stimulated 
with HO53 and HO56 (both at 75 µM) for 24 h, then infected with PAO1 for 1 h and the remaining extracellular 
bacteria were eliminated with gentamicin (100 µg/ml) treatment for 20 min. Intracellular bacteria are presented 
as a percentage of colony forming units (CFU) from untreated cells (Ctrl) showed as relative PAO1 number 
[%]. Gentamicin at low concentration (0.5 µg/ml) was used as a positive control. (b) The direct effect of the 
two APDs on PAO1 in the cell culture medium (BEGM) in absence of BCi cells, presented as CFU after 1 h 
direct exposure. Gentamicin at low concentration (1 µg/ml) and synthetic LL-37 peptide (1 µg/ml) were used 
as positive controls. (c) Pseudomonas aeruginosa PAO1 growth and d) viability after 2 h co-incubation with 
the two APDs in Luria Bertani (LB) medium. Independent experiments of 3 ± SEM, for (a,b and d) statistical 
significance was calculated using one-way ANOVA with Dunnett’s multiple comparisons test while comparing 
to untreated group (Ctrl) or with Sidak’s multiple comparisons test while comparing to solvent control group. 
For (c) statistical significance was calculated using two-way ANOVA with Dunnett’s multiple comparisons test, 
*p < 0.05, **p < 0.01, ****p < 0.0001. Significant changes are highlighted.
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24 h of treatment with HO53 (Supplementary Fig. S7d). In contrast to monolayer cells, the expression of TNF/
TNFα and CXCL8/IL-8 was not significant (Supplementary Fig. S7). In summary, we observed a different induc-
tion profile of antimicrobial effectors and cytokines/chemokines for differentiated cells in comparison to mon-
olayer cells.
HO53 counteracts disruptive effect of P. aeruginosa conditioned medium on airway epithelial integrity. 
Pathogens exhibit different strategies to evade the host epithelial surfaces. P. aeruginosa can disintegrate the junc-
tions between epithelial cells and enter tissue through the paracellular space42. Another strategy is the produc-
tion of virulence factors that can be injected into the host cells or secreted by bacteria to the environment, e.g. 
rhamnolipids43. We have shown that Pseudomonas aeruginosa PAO1 conditioned medium can disrupt epithelial 
barrier integrity44. Here we investigated if the treatment with HO53 can counteract the disruptive effect of PAO1 
conditioned medium (Fig. 6). BCi cells differentiated in ALI culture were pretreated with HO53 for three con-
secutive days and challenged with PAO1 conditioned medium applied on the apical side of ALI culture for 24 h. 
Azithromycin was used as a positive control (Supplementary Fig. S8). After 3 h exposure of control BCi cells to 
PAO1 conditioned medium, trans-epithelial electrical resistance (TEER) decreased from ~1200 Ω × cm2 to ~200 
Ω × cm2 and the disruptive effect was also observed after 6 h of exposure (Fig. 6a). The recovery of the tight junc-
tions (TJs) integrity was noted after 24 h post challenge. In contrast to the control cells, the pretreatment of the 
ALI culture with HO53 did not lead to a pronounced TEER drop (~1000 Ω × cm2 to ~700 Ω × cm2) and the epi-
thelial barrier integrity was restored after 5 h. To illustrate counteraction of TJ disruption, we performed confocal 
microscopy after 6 h of PAO1 conditioned medium challenge. Consistent with the TEER results, the disruption of 
zonula occludens (ZO-1) and occludin was observed in the control group, while HO53 treated group maintained 
TJs integrity (Fig. 6b). We further analyzed levels of the tight junction proteins occludin and claudin-1 at selected 
time points (0, 3, 6, 24 h) by Western blot analysis (Fig. 6c). The band corresponding to the main occludin isoform 
was faintly detected after 3 and 6 h of PAO1 conditioned medium challenge in the control group (the western 
blot analyses shows the occludin degradation/processing product, Supplementary Fig. S9) and did not reach the 
same expression level after 24 h. However, in the cells pretreated with HO53 occludin was not degraded. After 
3 h of challenge the occludin level was reduced, while after 6 h the expression was restored. Notably, induction of 
occludin expression was detected upon HO53 treatment, whereas there was no change in claudin-1 level (Fig. 6c). 
In conclusion, HO53 counteracted disruptive effect of PAO1 conditioned medium on respiratory epithelium via 
a novel mechanism affecting tight junctions.
STAT3 activation is required for HO53 mediated CAMP gene induction. It has been shown that 
Entinostat induces CAMP gene expression in gut epithelial cells via activation of STAT3 and HIF-1α transcrip-
tion factors29. HO53 is structurally related to Entinostat and here we investigated if the molecular pathways 
Figure 5. HO53 and HO56 enhance induction of additional innate immunity genes including cytokines in ALI 
differentiated BCi cells. Differentiated cells were used for experiments when TEER value reached approx. ≥ 1000 
Ω × cm2. Expression at mRNA level of (a) LCN2, (b) S100A8 and (c) subsequent protein level expression of 
NGAL and S100A8 analyzed by Western blot. GAPDH was used as loading control. The Western blot analysis 
was performed n = 2 with similar results. Full-length blots are presented in Supplementary Figure S10c. The 
mRNA level of (d) CAMP, (e) HBD1, (f) LYZ after 24 h (black bars) and 48 h (grey bars) stimulation with HO53 
and HO56 (both at 75 μM). Expression at mRNA level was analyzed by qRT-PCR and normalized to TUBB 
(tubulin-β) reference gene. Data is from n = 4 independent experiments ± SEM, statistical significance was 
calculated in comparison to untreated cells (Ctrl) using two-way ANOVA with Dunnett’s multiple comparisons 
test, *p < 0.05, **p < 0.01, ***p < 0.001. Significant changes are indicated.
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involved in the HO53 induced CAMP gene expression in bronchial epithelial cells follows similar pathways as 
described for the colon epithelial cell line HT-2929. For that, we examined the role of STAT3 by using the STAT3 
inhibitor Stattic (Fig. 7a,b). BCi cells were pretreated with increasing doses of the Stattic inhibitor (5 µM, 10 µM, 
and 20 µM) for 30 min followed by stimulation with HO53 for 24 h. We observed significant dose-dependent 
Stattic mediated decrease in CAMP gene expression (Fig. 7a). Transcription factor HIF-1α expression was also 
decreased in a dose-dependent manner as for the CAMP gene (Fig. 7b). Furthermore, we investigated if HO53 
treatment resulted in enhanced STAT3 expression or post-translational modifications (Fig. 7c). The expression 
level of STAT3 and phosphorylated-STAT3 was increased in a time dependent manner after treatment with 
HO53. The level of the phosphorylated STAT3 increased after 4 h and reached the maximum after 6 h of treatment 
with HO53. We did not observe any difference in the acetylation at Lys685 of STAT3 after treatment with HO53. 
However, modifications of other lysine residues of STAT3 cannot be excluded. HIF-1α expression level was grad-
ually elevated at 4, 6 and 8 h and at 24 h there was a prominent enhanced level of HIF-1α. In summary, STAT3 is 
most likely a central regulator of the CAMP gene induction by HO53 although other STAT3 modifications need 
to be evaluated to explain the detailed mechanism of the inducing effect of HO53.
Discussion
An increasing number of infections caused by antibiotic resistant pathogens contribute to higher morbidity/mor-
tality rate and generate high costs for the health care system45. Therefore, development of alternative strategies to 
conventional antibiotic therapy is urgently needed. Host directed therapy (HDT) based on inducing innate immu-
nity by enhancing expression of endogenous antimicrobial components or counteracting pathogen-mediated 
suppression of first line defenses could be an alternative27. HDT could limit the selection of antibiotic resistant 
strains and might be used against multidrug-resistant (MDR) bacteria.
Development of novel stable compounds for the induction of innate immunity would be beneficial. To 
approach this aim, a reporter cell line with the CAMP gene fused to the luciferase gene was established for screen-
ing induction of the CAMP gene expression35. Screening of compound libraries and selected HDAC inhibitors 
resulted in the identification of Entinostat, working against Shigella and Vibrio infections in rabbits30,31. Recently, 
Figure 6. HO53 treatment counteracts the disruptive effect of P. aeruginosa PAO1 conditioned medium in ALI 
differentiated BCi cells. Differentiated BCi cells (trans epithelial electrical resistance, TEER ≥ 1000 Ω × cm2) 
were treated with 75 μM HO53 in the lower chamber of transwell insert for 3 days and challenged with PAO1 
conditioned medium (PAO1 cond medium) applied on the apical surface of the cells for the next 24 h. (a) TEER 
measurement after every hour from 0 to 7 h and after 24 h post PAO1 culture medium challenge. Data shown 
is representative of two experiment and showing mean values of four independent ALI filters at each time 
point ± SEM. Samples for confocal microscopy and Western blot were collected at selected time points in order 
to analyze tight junctions (TJ) integrity. (b) Confocal images showing disruption of occludin (red) and ZO-1 
(green) after 6 h post PAO1 culture medium challenge of HO53 treated cells as compared to control cells (Ctrl), 
Bar = 10 µm. (c) Western blot analyses of occludin and claudin-1 after 0, 3, 6 and 24 h exposure to PAO1 culture 
medium. GAPDH was used as a loading control. The full-length blot for occludin is presented in Supplementary 
Figure S9 and for claudin-1 and GAPDH in Supplementary Figure S10d.
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a similar strategy for identification of other innate immunity inducers was described based on the induction of 
the defensins genes HBD2 and HBD346,47. Another interesting approach was through the pattern recognition 
receptor NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), when activation of this receptor 
by N-phosphonacetyl-L-aspartate (PALA), was identified as a potent inducer of innate immunity. Expression of 
HBD2 and CAMP were induced by PALA and antimicrobial activity was demonstrated in skin explants against 
bacteria including methicillin-resistant Staphylococcus aureus (MRSA)48.
In the current study we describe that the novel APD compounds HO53 and HO56 induced a broad spec-
trum of antimicrobial effectors in bronchial epithelium. Both compounds are developed as AMP inducers with 
increased water solubility, lower cytotoxicity and reduced effects on cell proliferation as compared to Entinostat. 
We mainly used the BCi-NS1.1 (BCi) cell line41 but the induction of the CAMP gene expression was also con-
firmed in the VA10 cell line49. The gene induction profiles of HO53, HO56 and Entinostat were similar with 
reference to time but not with reference to the concentration. The dose studies utilizing BCi cells revealed a 
concentration dependent response for HO53 and HO56, but not for Entinostat (Fig. 1b; Supplementary Fig. S3) 
most likely due to higher cytotoxicity of the latter. Interestingly, when HO53 and HO56 were tested with the 
known innate immunity inducers vitamin D3 and PBA, a synergistic induction of the CAMP gene expression was 
noted with vitamin D3 but not with PBA. This suggests that APDs and PBA possibly act through the same sign-
aling pathways. PBA and Entinostat are known HDAC inhibitors28,32, however today this activity is referred to as 
lysine deacetylases inhibition (KDACi) because apart from histones also cytoplasmic signaling pathway proteins 
are affected50. Indeed, the suggested mechanism of Entinostat activity included acetylation of the cytoplasmic 
Figure 7. STAT3 and HIF-1α mediate CAMP gene induction by HO53 in BCi cells. The effect of the STAT3 
inhibitor Stattic on (a) CAMP and (b) HIF1A expression in BCi cells. Cells were pretreated with 5, 10 and 
20 µM of Stattic for 30 min and then stimulated with HO53 (75 µM) for 24 h. CAMP and HIF1A expression was 
analyzed by qRT-PCR and normalized to TUBB (tubulin-β) reference gene. The data (a,b) represent mean of 
n = 4 independent experiments ± SEM. Statistical significance for HO53 and Stattic 10 µM was calculated in 
comparison to control (Ctrl), while the inhibitory effect of Stattic refers to HO53 alone using one-way ANOVA 
with Sidak’s multiple comparisons test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Significant 
alterations are highlighted. (c) Effect of HO53 (75 µM) treatment of BCi cells on STAT3 phosphorylation 
(p-STAT3 at Tyr705), total STAT3, acetylation (Acetyl-STAT3 at Lys685) and HIF-1α expression after 2, 4, 6, 
8 and 24 h was analyzed by Western blot. GAPDH served as a loading control. The experiment was performed 
n = 2 with similar results. Full-length blots are presented in Supplementary Figure S10e.
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signaling protein STAT329. Therefore, possible KDAC inhibition by the novel APD compounds must be experi-
mentally confirmed.
For both novel APDs we found induced antimicrobial activity in BCi cells against Pseudomonas aeruginosa 
(PAO1) and the disruptive effect of PAO1 on epithelial integrity was counteracted by HO53. This double effect 
of HO53 on the epithelial barrier might be potentially beneficial in vivo for fending off bacterial intruders and 
blocking bacterial translocation. Thus, HO53 would be an interesting candidate to treat and/or prevent infections. 
Interestingly, the antimicrobial activity was assessed against Pseudomonas aeruginosa that is prevalent in immune 
compromised lungs, including cystic fibrosis patients. The characteristics of the cellular response to treatment 
with HO53 suggest an effective HDT compound that might be beneficial for cystic fibrosis patients and used 
against MDR strains.
Induction of the CAMP gene expression served as a reference for the selection of HO53 and HO56 com-
pounds. We selected additional genes encoding peptides/proteins with known defense functions at epithelial 
surfaces such as lipocalin 2, HBD1, S100A8, lysozyme and lactoferrin to verify whether the induced expression 
would mimic in vivo defenses. Significant induction of lipocalin 2, HBD1 and S100A8 expression was observed 
at mRNA and protein levels, indicating the APD compounds as powerful activators of a broad spectrum defense. 
Kinetics of mRNA and protein induction were not strictly correlated, where the most pronounced deviation was 
for HBD1 expression with a fold change of mRNA from 50 to 100, while at protein level only approximately 2 
times changed (Fig. 2c,d). Similar differences were also observed for lipocalin 2, indicating a regulation at trans-
lational level in the cells. However, the current overall expression profile shows a broad induction of multiple 
polypeptides. In addition, we estimated the influence of APDs on reactive oxygen species (ROS) and nitric oxide 
(NO) production. ROS was not affected but the expression of NOS2 (encoding inducible nitric oxide synthase 
iNOS) was enhanced. However, this enhancement was not confirmed on effector level by the Griess method, 
measuring nitrate in solution probably due to low concentrations. The observed antimicrobial effect in our sys-
tem is unlikely due to enhanced NO production. However, low induction of the iNOS protein may contribute to 
the antimicrobial effect in vivo. Thus, the main antibacterial activity in our model is most likely due to increased 
expression of antimicrobial proteins/peptides and could even be enhanced in the in vivo situation with complete 
processing of active components.
We analyzed the induction of different innate immunity effectors expression both in monolayer BCi cells 
and air liquid interphase (ALI), thereby comparing basal like cells with differentiated epithelial cells41. Several 
differences were observed: (1) the mRNA expression for lysozyme (LYZ) was not detected in monolayer but 
was inducible in differentiated cells (Fig. 5f), (2) induction of S100A8 expression was more pronounced in ALI 
culture (S100A8 could not be detected in undifferentiated cells). (3) In contrast, the HBD1 expression was more 
pronounced in undifferentiated cells. (4) The expression of pro-inflammatory effectors like, TNF/TNF-α and 
CXCL8/IL-8 was significantly enhanced in monolayer cells (Fig. 3) but not in ALI cultured cells, except IL1B 
expression (Supplementary Fig. S7). These differences indicate that the undifferentiated cells are more sensitive 
to external stimuli and trigger NF-kB regulated responses, which might be linked to their basal functions. The 
different responses can also reflect different transcription factors setup and chromatin accessibility in the basal 
cells versus polarized cells.
In the experiments for approaching molecular mechanism and epithelial integrity we selected HO53 because 
of lower cytotoxic effects on BCi cells, higher yields from the synthesis and better solubility than HO56. One 
suggested mechanism for induction of innate immunity by Entinostat included two steps: first, activation of 
STAT3 by acetylation and second, subsequent increase of HIF-1α29. Notably, the transcription factor HIF-1α has 
been confirmed important for transcription of innate immunity genes51. Because the new APDs are structurally 
related to Entinostat, we tested the effect of HO53 in relation to the STAT3 transcription factor using a specific 
inhibitor - Stattic. By blocking STAT3 we observed significant reduction of CAMP and HIF1A expression upon 
HO53 treatment. Furthermore, upon HO53 treatment there was a time dependent increase of the STAT3 protein 
and in particular a pronounced effect on the phosphorylation of STAT3, whereas the acetylation status at Lys685 
was unchanged. Gradually increased expression of HIF-1α was detected with time after stimulation of the cells by 
HO53. In conclusion, STAT3 seems to be an important mediator of the APD response but more detailed studies 
on STAT3 modifications are needed that might define the cellular target of HO53.
In gut epithelia STAT3 mediated expression of occludin was shown to enhance tight junction function and 
prevent bacterial translocation52. HO53 treatment led to increased occludin expression (Fig. 6) that could be 
an explanation for limited disruption of tight junctions (TJs) caused by Pseudomonas. This type of counterac-
tion was initially identified on polarized lung epithelium for the antibiotic azithromycin (AZM) by an unknown 
mechanism44. Here, we confirmed the effect by AZM (Supplementary Fig. S8), but interestingly the HO53 effect 
seemed to be more potent in rescuing the barrier integrity than AZM. Together all these effects of HO53 do 
not only underline the double action of the molecule but also highlights the importance of STAT3 in epithelial 
immunity53,54.
Our results warrant continuation in animal infection models and motivate pharmacodynamics and pharma-
cokinetic studies. Usage of the APDs could re-establish the niche for the natural microbiota and avoid selection 
of resistant bacteria in line with improvement of stewardship in healthcare.
Materials and Methods
Reagents and materials. Entinostat (SNDX-275), 1α,25-dihydroxyvitamin D3 (D1530), collagen from 
human placenta (C7521), Stattic inhibitor (S7947), LB broth (L3522), agar (05039-500G), gentamicin (G1914), 
methanol (34885-2.5L), menadione (M5625), the secondary antibodies conjugated with HRP for Western blot-
ting (A5420 and A0545), DAPI (D9564) were purchased from Sigma. UltroserG (UG, 15950-017) was obtained 
from PALL Life Sciences and sodium 4-phenylbutyrate (2682) from Tocris Bioscience. Synthetic LL-37 peptide 
(SP-LL37) was bought from Innovagen and DMSO (sc-358801) from Santa Cruz. Azithromycin (Zitromax) of 
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500 mg was from Pfizer. The monoclonal anti-LL-37 antibody was generated by us and described in Yoshio et al.55. 
Anti-ZO-1 (#13663), anti-STAT3 (#9139), anti-acetyl-STAT3 (#2523), anti-phospho-STAT3 (#9145) and anti-
GAPDH (#2118) antibodies were purchased from Cell Signaling Technology. Anti-lipocalin 2 (AF1757) antibody 
was obtained from R&D Systems, anti-HIF-1α (ab113642) antibody was from Abcam and anti-occludin (331500) 
and anti-claudin-1 (51-9000) antibodies from Thermo Scientific. Secondary antibodies for immunofluorescence 
staining were obtained from Thermo Scientific (A-11070 and A-11020). 2-Azidoethanol was synthesized accord-
ing to a published procedure and distilled under reduced pressure56. All other synthesis reagents and solvents 
(analytical grade) were purchased from commercial sources and were used without further purification. The 
NMR spectra were collected on a Bruker DRX-400 spectrometer (400 MHz for 1H and 101 MHz for 13C) with 
the residual solvent signal as chemical shift reference. Mass spectra were recorded on a Micromass LCT (ESI-
TOF) mass spectrometer.
Cell cultures. The human bronchial epithelial cell line BCi-NS1.1 (BCi) immortalized with retrovirus 
expressing human telomerase (hTERT) was from dr Matthew S. Walters, Weill Cornell Medical College, New 
York NY, USA41. An E6/E7 viral oncogene immortalized human bronchial epithelial cell line VA10 has been 
described previously49. Both cell lines were cultured in Bronchial/Tracheal Epithelial cell growth medium 
(BEGM) (Cell Applications, 511A-500) supplemented with retinoic acid (Cell Applications, 511-RA) and 
Penicillin-Streptomycin ((20 U/ml, 20 µg/ml, respectively) (Life Technologies, 15140122)) at 37 °C and 5% CO2. 
The ALI (air-liquid interface) culture of BCi cells were maintained as described previously41. Cells in monolayer 
were treated with HO53 and HO56 by direct addition to the culture medium. Differentiated BCi cells were used 
for experiments when TEER value of ≥1000 Ω × cm2 was reached and then HO53 and HO56 were added to the 
lower chamber for indicated period of time. Azithromycin was used as a control.
Bacterial culture. The overnight culture of Pseudomonas aeruginosa PAO1 strain was diluted in LB medium 
to OD590 = 0.05 and cultured at 37 °C with 180 rpm shaking until the bacterial subculture reached the mid-log 
phase.
RNA analysis. Total RNA was extracted using Nucleo Spin RNA kit (Machinery-Nagel, 740955.50). Total 
RNA of 1 µg was used to synthesize complementary DNA (cDNA) according to the manufacture’s recommen-
dations using the High Capacity cDNA reverse transcriptase kit (Applied Biosystems, 4368814). One µl of 
cDNA, 5 µl of PowerUp SYBR Green Master Mix (Applied Biosystems, A25742) and 0.5 µM primers enlisted in 
Supplementary Table S1 were used for qRT-PCRs. The qRT-PCRs were performed using LG 7500 Real Time PCR 
System (Applied Biosystems) with the following cycling conditions: (1) holding stage: 95 °C for 10 min, followed 
by 40 cycles of (2) denatured stage: 95 °C for 15 s and (3) annealed/extended stage: 60 °C for 1 min. The 2(−ΔΔCT) 
Livak method was utilized for calculating fold differences over untreated control57.
Immunoblotting. Cells were washed with PBS and lysed in RIPA lysis buffer (Santa Cruz, sc-364162) sup-
plemented with Halt Protease Inhibitor Cocktail (Thermo Scientific, 87786) on ice for 30 min. The cell culture 
media in the volume of 2 ml were concentrated as it has been described earlier58. The concentrated culture media 
or 10–30 µg of total protein content was separated using NuPAGE 4–12% Bis–Tris gradient gel (Life Technologies, 
NP0323), NuPAGE MES SDS Running Buffer (Life Technologies, NP0002) and the running conditions were 
120 V and 275 mA. The proteins were transferred on to a PVDF membrane (0.2 µm pores) using XCell IITM Blot 
Module (Invitrogen, EI9051) and the membrane was blocked with 10% skimmed milk or 5% BSA in TBS-T buffer 
(50 mM Tris, 150 mM NaCl, 0.1% Tween-20) for 1 h at room temperature. Then, the membrane was incubated 
with primary antibodies overnight at 4 °C using a dilution recommended by the manufacturer’s protocol. After 
washing with TBS-T buffer the membrane was incubated with horse radish peroxidase (HRP) conjugated second-
ary antibodies (1:10 000 dilution) in 5% skimmed milk or 5% BSA in TBS-T for at least 1.5 h at room temperature. 
Immunoblots were developed using Pierce ECL Plus Western blotting substrate (Thermo Scientific, #34095) or 
Western blotting Luminol reagent (Santa Cruz, sc-2048) and ImageQuant LAS 4000 system (GE Healthcare). 
Quantification of the band intensity was performed using ImageJ software.
eLIsA. Sandwich enzyme-linked immunosorbent assays (ELISAs) were performed utilizing a human beta 
defensin-1 (hBD-1), interleukin 8 (CXCL8) and tumor necrosis factor alpha (TNFα) assay kit according to the 
manufacturer’s instructions (Peprotech, UK). The results are represented from three independent experiments.
Cytotoxicity and cell viability assays. BCi cells (10,000) were seeded in 96-well plate chambers in 200 µl 
of BEGM. Once adhesion was verified, cells were incubated with different concentrations of Entinostat (2.5–
50 µM), HO53 (2.5–250 µM) and HO56 (2.5–250 µM) along with the known CAMP inducer PBA (4 mM) for 
24 h. Cytotoxicity and cell proliferation was determined using CytoTox 96® Non-Radioactive Cytotoxicity Assay 
(Promega, G1781) kit and Cell Proliferation Reagent WST-1 (Roche, 05015944001), respectively, according to the 
manufacturer’s instructions. The results presented were from three independent experiments for cytotoxicity and 
two independent experiments for cell proliferation.
Antimicrobial assays. BCi cells in monolayer were treated for 24 h with APDs or low dose of gentamycin 
(0.5 µg/ml) used as a positive control and then infected with PAO1 using MOI ~40 for 1 h. Cells were then washed 
3 times with PBS and incubated for 20 min with medium containing 100 µg/ml gentamicin (bacterial killing 
concentration). Cells were washed again, lysed in 0.1% Triton X-100/H2O (v/v) for 5 min, serially diluted in PBS 
and plated on LB agar plates. After overnight incubation at 37 °C, the PAO1 CFU (colony forming units) were 
enumerated.
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Ros detection. The H2O2 level in the cell culture medium after 24 h of treatment with HO53 and HO56 
(both at 75 µM) was measured using ROS-GloTM H2O2 assay (Promega, G8820) according to the manufacture’s 
protocol.
Agarose gel electrophoresis. Semi-quantitative PCR products were separated on 1.5% agarose gel contain-
ing ethidium bromide (0.5 µg/ml). Electrophoresis was run at 80 V for 30 min using 1x TAE (Tris-acetate-EDTA) 
buffer. β-tubulin was used as a control for the quantification of the band intensity using ImageJ software.
Preparation of PAO1 conditioned medium and challenge of differentiated BCi cells. Wild-type 
(WT) P. aeruginosa strain PAO1 was used to prepare bacterial conditioned medium. Shortly, the bacteria were 
cultured in Dulbecco’s Modified Eagle Medium F-12 Nutrient Mixture (DMEM/F12) + 2% UltroserG (UG) at 
30 °C and shaking was at 180 rpm for 5 days. Bacterial culture supernatants were collected, vortexed thoroughly, 
centrifuged, and filtered through 0.22 mm pore-size filter (GE Healthcare and Life Science, Whatman, Germany). 
BCi cells were cultured at the ALI for 3 weeks with medium changed every 2–3 days to get differentiated cells, 
followed by placing HO53 (75 µM diluted in DMEM/F12 + 2% UG) in the basal chamber of the transwell insert 
for 3 consecutive days, while Azithromycin was used as positive control as described previously44. Next, differen-
tiated cells were challenged with PAO1 conditioned medium and TEER was measured after every hour. Samples 
for Western blot and confocal microscopy analyzes were collected at selected time points.
Immunofluorescence staining and confocal microscopy. BCi cells growing on ALI filters were fixed 
using chilled methanol at 4 °C overnight followed by chilled acetone. Briefly, staining was done as follows: filters 
were hydrated with IF buffer (PBS + 0.3% Triton X-100), blocked with 10% FBS, washed and incubated with a 
primary antibody overnight at 4 °C. The following primary antibodies were used: rabbit anti-occludin and mouse 
anti-ZO-1. Next day the filter was washed and incubated with a secondary antibody for 2 h. For immunofluores-
cence staining, isotype-specific Alexa Fluor secondary antibody conjugates were used and DAPI was used to stain 
nuclei. The filter was then washed with IF buffer and finally rinsed with water. Cell culture transwell filters were 
mounted in Fluoromount™ Aqueous Mounting Medium (F4680-Sigma) and coverslips were placed over the 
filters. Images were captured using Olympus fluoview Fv1200 confocal microscope at 30x magnification. Z-scans 
were performed by taking series of images at the same location with fixed focal intervals.
statistical analysis. Results are presented as mean ± standard error of mean (SEM) from at least three inde-
pendent experiments, otherwise it is indicated in the figure legends. One- or two-way ANOVA with post-hoc 
Dunnett’s or Sidak’s multiple comparisons test were used to determine significance of the data. p values are 
included in the figure legends. The statistical analysis were performed with GraphPad Prism 6 software (Graph 
Pad, USA). The Western blots are representative of at least two independent experiments.
Data Availability
The data generated during and/or analysed during the current study are available from the corresponding author 
on reasonable request.
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